First dose of potential new medicines to humans: how animals help

The need for careful testing of new drugs in animal models before study in humans has been recognised by physicians since the First World War. Now, first human studies on new drugs are subject to detailed government guidelines, which in the European Union are presently being reinforced through the wide-ranging Clinical Trials Directive. However, despite their long history and widespread application, these guidelines are empirical and have been formulated with a paucity of critical scientific evidence. Here, we review the principles and the available, albeit limited, evidence that support the design and conduct of preclinical studies in a way that permits effective and safe first-dose studies of potential new medicines in humans.

[1]  S. R. Fine,et al.  ADVERSE DRUG REACTIONS , 2009, BMJ : British Medical Journal.

[2]  B. Fermini,et al.  The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.

[3]  Peter Greaves,et al.  Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation , 2000 .

[4]  S. Marsoni,et al.  Relation of preclinical toxicology to findings in early clinical trials. , 1986, Cancer treatment reports.

[5]  D. Rall,et al.  The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man , 1970, Clinical pharmacology and therapeutics.

[6]  R D Combes,et al.  Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  J. Dean,et al.  Immunotoxicology assessment in the pharmaceutical industry. , 1998, Toxicology Letters.

[8]  E. Shuster.  Fifty years later: the significance of the Nuremberg Code. , 1997, The New England journal of medicine.

[9]  J. Doull,et al.  The role of time as a quantifiable variable of toxicity and the experimental conditions when Haber's c x t product can be observed: implications for therapeutics. , 2001, The Journal of pharmacology and experimental therapeutics.

[10]  O. Svendsen,et al.  A comparative study of serum creatine phosphokinase (CPK) activity in rabbits, pigs and humans after intramuscular injection of local damaging drugs. , 2009, Acta pharmacologica et toxicologica.

[11]  G. Zbinden,et al.  Toxicological assessment of the hemostatic system, regulatory requirements, and industry practice. , 1984, Regulatory toxicology and pharmacology : RTP.

[12]  C. S. Weil,et al.  Correlation of human hepatotoxicants with hepatic damage in animals. , 1982, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[13]  P. Cannon,et al.  PATHOLOGIC EFFECTS OF ELIXIR OF SULFANILAMIDE (DIETHYLENE GLYCOL) POISONING: A CLINICAL AND EXPERIMENTAL CORRELATION: FINAL REPORT , 1938 .

[14]  A. S. Davis.  The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods , 1998, Human & experimental toxicology.

[15]  F. Ponti,et al.  QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience , 2000, European Journal of Clinical Pharmacology.

[16]  R. Colin Garner,et al.  Big physics, small doses: the use of AMS and PET in human microdosing of development drugs , 2003, Nature Reviews Drug Discovery.

[17]  J. Lanchbury,et al.  Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. , 1998, Arthritis and rheumatism.

[18]  A. Fletcher,et al.  Drug Safety Tests and Subsequent Clinical Experience , 1978, Journal of the Royal Society of Medicine.

[19]  J. Litchfield.  Forecasting drug effects in man from studies in laboratory animals. , 1961, JAMA.

[20]  T. Igarashi,et al.  Predictability of clinical adverse reactions of drugs by general pharmacology studies. , 1995, The Journal of toxicological sciences.

[21]  J. Dean.  Issues with introducing new immunotoxicology methods into the safety assessment of pharmaceuticals. , 1997, Toxicology.

[22]  Recommendations guiding physicians in biomedical research involving human subjects. World Medical Association Declaration of Helsinki. , 1994, Le Journal medical libanais. The Lebanese medical journal.

[23]  W. E. Ribelin.  The effects of drugs and chemicals upon the structure of the adrenal gland. , 1984, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[24]  M. Akaike,et al.  A Collaborative Study in Japan on Optimal Treatment Period and Parameters for Detection of Male Fertility Disorders Induced by Drugs in Rats , 1995 .

[25]  E J Freireich,et al.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. , 1966, Cancer chemotherapy reports.

[26]  A. M. Monr.  The Role of Metabolish Studies in Drug Safety Evaluation , 1976 .

[27]  P. Raskin,et al.  Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. , 1998, The New England journal of medicine.

[28]  A. Monro,et al.  Are single‐dose toxicology studies in animals adequate to support single doses of a new drug in humans? , 1996, Clinical pharmacology and therapeutics.

[29]  A. Owens.  Predicting anticancer drug effects in man from laboratory animal studies. , 1962, Journal of Chronic Diseases.

[30]  E. Shuster.  The Nuremberg Code: Hippocratic ethics and human rights , 1998, The Lancet.

[31]  C. Lau,et al.  Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. , 1998, Arthritis and rheumatism.

[32]  P Smith,et al.  Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.

[33]  Harkness Jm.  The significance of the Nuremberg Code. , 1998 .

[34]  Romualdo Benigni,et al.  Designing safer drugs: (Q)SAR-based identification of mutagens and carcinogens. , 2003, Current topics in medicinal chemistry.

[35]  D. Clive.  Mutagenicity in drug development: interpretation and significance of test results. , 1985, Regulatory toxicology and pharmacology : RTP.

[36]  J. Degeorge,et al.  Response to Monro and Mehta proposal for use of single‐dose toxicology studies to support single‐dose studies of new drugs in humans , 1996, Clinical pharmacology and therapeutics.

[37]  D. Dinsdale,et al.  Detecting and evaluating chemical-induced lung damage in experimental animals. , 1987, Bulletin europeen de physiopathologie respiratoire.

[38]  L. G. Bartholomew,et al.  Abdominal exploration for gastrointestinal bleeding of obscure origin. , 1961, JAMA.

[39]  Joy A. Cavagnaro,et al.  Preclinical safety evaluation of biotechnology-derived pharmaceuticals , 2002, Nature Reviews Drug Discovery.

[40]  S. Walker,et al.  Trends in the development of new medicines by UK-owned pharmaceutical companies (1964-1980). , 1986, British journal of clinical pharmacology.

[41]  R. Andrade,et al.  Drug-induced hepatotoxicity , 2003, The New England journal of medicine.

[42]  Edward J Calabrese,et al.  Toxicology rethinks its central belief , 2003, Nature.

[43]  M. Orme.  Animal Toxicity Studies: Their Relevance for Man , 1991 .

[44]  Report of validation study of assessment of direct immunotoxicity in the rat. The ICICIS Group Investigators. International Collaborative Immunotoxicity Study. , 1998, Toxicology.

[45]  D. Amacher.  Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. , 1998, Regulatory toxicology and pharmacology : RTP.

[46]  J. Dressman,et al.  Comparison of Canine and Human Gastrointestinal Physiology , 1986, Pharmaceutical Research.

[47]  Cavero,et al.  QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. , 1999, Pharmaceutical science & technology today.